News

A combination of Pomalyst (pomalidomide) and low-dose dexamethasone is cheaper than either Darzalex (daratumumab) or Kyprolis (carfilzomib) alone as a treatment for relapsed or refractory multiple myeloma (RRMM), a study shows. The research, published in Clinical Therapeutics, is titled “Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the…

Cellectar Biosciences is expanding its Phase 1 dose-escalating trial to evaluate the effectiveness and safety of multiple administrations of CLR 131 for the treatment of relapsed or refractory multiple myeloma. The trial’s fifth group of patients will receive two 15.625 mCl/m2 doses of CLR 131, one week apart. The combined dose…

Patients with relapsed and refractory multiple myeloma lived roughly 3.6 months longer without their disease worsening when they received a once-weekly dose of Amgen’s Kyprolis (carfilzomib) compared to a twice-weekly dose, according to an interim analysis of a Phase 3 trial. Both treatment regimens included the administration of dexamethasone,…

Multiple myeloma patients with high levels of the EZH2 enzyme have shorter survival times, regardless of the treatment they receive, a British study reports. The research, “Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control,” appeared in the…

A new study reports that the specific type of multiple myeloma (MM) may affect how long the drug Darzalex (daratumumab) remains in circulation, affecting its effectiveness for the treatment and management of the disease. Results from the study, “Influence of Disease and Patient Characteristics on Daratumumab Exposure…

The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by National Health Service (NHS) in Scotland, has amended its initial decision and now recommends Janssen’s Darzalex (daratumumab) for patients with relapsed or refractory multiple myeloma. The decision was made after the pharmaceutical company offered to…

Myeloma UK has launched a new clinical trial to identify the best treatment options for myeloma patients classified as high-risk. The study is the first of its kind in the U.K. and one of the few that focus on high-risk myeloma patients, who represent a sub-group with urgent, unmet…

Adding Venclexta (venetoclax) to Velcade (bortezomib) and dexamethasone has shown promising effectiveness and an acceptable safety profile in multiple myeloma patients who progressed during or after at least one prior therapy, data from a Phase 1b clinical trial show. Among patients who received a median of three prior therapies, 67%…

An old blood-pressure-lowering therapy known as a diuretic killed multiple myeloma cells in a lab and in mice, including those resistant to current treatments, Spanish researchers reported. A combination of the therapy, amiloride, and existing myeloma drugs could be a good way to treat patients whose cancer has returned, the team…

The first patient with relapsed/refractory multiple myeloma has been treated with the investigational therapy bb21217, according to the clinical-stage company bluebird bio. The treatment candidate bb21217, developed under a joint collaboration of bluebird bio and Celgene, is being tested in the two-part open-label Phase 1 CRB-402 study (NCT03274219),…